Live Breaking News & Updates on Prnewswire Scopus Biopharma Inc
Stay updated with breaking news from Prnewswire scopus biopharma inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Scopus BioPharma Announces IND Submission to FDA for Lead Drug Candidate prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Scopus BioPharma Announces IND Submission to FDA for Lead Drug Candidate prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Scopus BioPharma Finalizes Arrangements for Submission of IND Package Submission to FDA Expected in Q2 2021 News provided by Share this article NEW YORK, March 15, 2021 /PRNewswire/ Scopus BioPharma Inc. (Nasdaq: SCPS ) today announced the finalization of arrangements for the completion of the investigational new drug ( IND ) package for the company s lead drug candidate and its submission to the United States Food and Drug Administration ( FDA ). The IND submission is expected in Q2 2021. Scopus is a biopharmaceutical company developing transformational therapeutics based on groundbreaking scientific and medical discoveries. The company s lead drug candidate is a novel, targeted immuno-oncology gene therapy for the treatment of multiple cancers. ....
Share this article NEW YORK, Feb. 10, 2021 /PRNewswire/ Scopus BioPharma Inc. (Nasdaq: SCPS) today announced the closing of the underwriters over-allotment option in full, bringing total follow-on public offering proceeds to $10.35 million. Scopus is a biopharmaceutical company developing transformational therapeutics based on groundbreaking scientific and medical discoveries. The company s lead drug candidate is a novel, targeted immuno-oncology gene therapy for the treatment of multiple cancers. Scopus intends to use the total proceeds of the follow-on public offering, including the proceeds from the exercise of the over-allotment option, principally for further development of the company s lead drug candidate, including in combination with checkpoint inhibitors. ....
Press release content from PR Newswire. The AP news staff was not involved in its creation. Underwriters Exercise Over-Allotment Option in Full, Brings Total Follow-On Public Offering Proceeds to $10.35 Million February 9, 2021 GMT (PRNewsfoto/Scopus BioPharma Inc.) NEW YORK, Feb. 8, 2021 /PRNewswire/ Scopus BioPharma Inc. (Nasdaq: SCPS) today announced that the underwriters of the company’s follow-on public offering exercised their over-allotment option in full, bringing total proceeds to $10.35 million. The exercise of the over-allotment option is expected to close on or about February 10, 2021, subject to customary closing conditions. Scopus is a biopharmaceutical company developing transformational therapeutics based on groundbreaking scientific and medical discoveries. The company’s lead drug candidate is a novel, targeted immuno-oncology gene therapy for the treatment of multiple cancers. ....